Chinese Academy of Sciences

Shanghai Haihe Pharmaceutical Co., Ltd.

Shanghai Fochon Pharmaceutical Co., Ltd.

Chongqing Fochon Pharmaceutical Co., Ltd.

Shanghai Puyi Chemical Co., Ltd.

Fochon Biosciences, Ltd.

Shanghai Theorion Pharmaceutical Co., Ltd.

Linghua Meng

Jian Ding

Yi Chen

Xiang Wang

Chunhao Yang

Cun Tan

Fajun Nan

Yangming Zhang

Jiapeng Li

Yanhong Chen

Jing Li

Jia Tao Li

Weibo Wang

Meiyu Geng

Fei Chen

Xingdong Zhao

Yubo Zhou

Xi Zhang

Xianlong Wang

Xin Xie

Rui Tan

Zuwen Zhou

Yanxin Liu

Jianping Zuo

Tongshuang Li

Jing Sun

Lihua Jiang

Ling Chen

Qihong Liu

Mingbo Su

Yue Rong

Lijun Yang

Min Gu

Li Linghu

Qian He

Chuiliang Yu

Shixian Wang

Linqian Yu

Na Yang

Jia Li

Haoyue Xiang

The present disclosure relates to 7-substituted pyrrolo[2,1-f][1,2,4]triazine compounds or pharmaceutically acceptable salts thereof, and preparation methods and uses thereof. These compounds show good PI3K inhibitory activity, can effectively inhibit the activity of PI3K kinase, and has significant enhancement and improvement of pharmacokinetic properties, such as bioavailability, due to the introduction of the 7-position group; furthermore, the compounds of the present disclosure exhibit an unpredictable high selectivity and strong inhibitory activity on PI3K&#x3b4;, and thus these compounds can be used for treating diseases related to PI3K pathway, especially for anti-cancer or for the treatment of tumors, leukemias and autoimmune diseases. After further optimizing and screening, the compounds are expected to be developed into a new type of anti-tumor drugs.

7-site substituted pyrrole triazine compounds or pharmaceutically acceptable salts thereof, and preparation method thereof and uses thereof

Provided are certain PI3K inhibitors, pharmaceutical compositions thereof, and methods of use therefor.

Certain protein kinase inhibitors

The present invention relates to a pyrrolo[2,1-f][1,2,4]triazine compound, an isomer thereof or a pharmaceutically acceptable salt, ester or hydrate thereof, and a preparation method and application thereof. The pyrrolo[2,1-f][1,2,4]triazine compound has a structure expressed in general formula (I). The pyrrolo[2,1-f][1,2,4]triazine compound expressed in general formula (I) can inhibit a phosphatidylinositol-3 kinase (PI3K) signal pathway, thereby being used to prepare medicine for treating phosphatidylinositol-3 kinase related diseases such as cancer.

Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof

[object Object]

The present invention relates to thiazole compounds of formula I, the method for preparation and use thereof. More specifically, the present invention relates to novel derivatives of natural product largazole, the method for preparing them and their uses for treatments against tumor and multiple sclerosis as inhibitors of histone deacetylase. 

Thiazole compounds, methods for preparation and use thereof

Rapalogs of formula I, pharmaceutically acceptable salts, pharmaceutical compositions, and preparation methods and uses thereof. The rapalogs have the structure of formula I and can be used as an anti-tumor medicament. Comparing with rapamycin, the rapalogs of the present invention exhibit enhanced water solubility, and improved pharmacological and pharmacokinetic properties by introducing a hydrophilic and polar group such as a hydroxyl. 

Rapamycin carbonic ester analogues, pharmaceutical compositions, preparations and uses thereof

Growing community of inventors

Shanghai, China

Linghua Meng